ChromaDex announced promising new findings based on a previously published clinical trial of company’s proprietary Niagen ingredient , which was supported by the ChromaDex External Research Program CERP . The new study, published in the peer-reviewed journal Aging Cell, was led by Dr. Christopher R. Martens, Department of Kinesiology & Applied Physiology, University of Delaware, USA, in collaboration with scientists from the National Institute on Aging . The study investigated whether NR would positively augment nicotinamide adenine dinucleotide levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles found in blood plasma. NEVs are nano-sized particles that are released by neurons in the central nervous system, including the brain, and circulate in blood plasma. They can contain RNA, DNA, and/or proteins that provide information relating to the metabolism of their tissue of origin, and serve as signaling molecules between various cells, tissues, or organs. Some scientists are investigating extracellular vesicles as biomarkers of disease development and progression. The present study demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Ass42, a biomarker for Alzheimer’s disease . "We believe biomarkers of brain health are continuing to develop and will be of great importance as humans live longer, especially as age is the number one risk factor for most conditions seen in older adults," said Rob Fried, CEO of ChromaDex. "Further, this study builds upon a previous breakthrough clinical study we recently announced, which we believe demonstrated the promising effects of NR supplementation on Parkinson’s disease patients and will pave the way for future brain-related research."
Published first on TheFly
